MRK Merck & Co Inc

  1. Stocks
  2. Healthcare
  3. NYSE: MRK

Price (delayed)

$130.2

Market cap

$321.57B

P/E Ratio

36.47

Dividend/share

$3.36

EPS

$3.57

Enterprise value

$365.36B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 72

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives ...

Highlights
The revenue has grown by 2.9% YoY
The P/E is 105% higher than the last 4 quarters average of 17.8 but 48% lower than the 5-year quarterly average of 70.8
The EPS has plunged by 51% from the previous quarter and by 48% YoY
The net income has dropped by 51% since the previous quarter and by 49% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.merck.com
Peers: PFE JNJ LLY BMY

Key stats

What are the main financial stats of MRK

MRK stock price

How has the Merck stock price performed over time
Intraday
0.32%
1 week
-0.66%
1 month
1.32%
1 year
66.67%
YTD
23.69%
QTD
1.32%

Financial performance

How have Merck's revenue and profit performed over time
Revenue
$65.77B
Gross profit
$48.61B
Operating income
$11.96B
Net income
$8.94B
Gross margin
73.9%
Net margin
13.6%
MRK's net margin has dropped by 52% since the previous quarter and by 50% year-on-year
The net income has dropped by 51% since the previous quarter and by 49% year-on-year
Merck's operating income has decreased by 44% from the previous quarter and by 41% YoY
Merck's operating margin has decreased by 44% QoQ and by 42% YoY

Price vs fundamentals

How does MRK's price correlate with its fundamentals

Growth

What is Merck's growth rate over time

Valuation

What is Merck stock price valuation
MRK P/E details
P/E
36.47
P/B
7.02
P/S
4.89
EV/EBIT
27.78
EV/EBITDA
18.83
EV/Sales
5.56
The P/E is 105% higher than the last 4 quarters average of 17.8 but 48% lower than the 5-year quarterly average of 70.8
The EPS has plunged by 51% from the previous quarter and by 48% YoY
The price to book (P/B) is 43% higher than the last 4 quarters average of 4.9 and 21% higher than the 5-year quarterly average of 5.8
Merck's equity has decreased by 13% from the previous quarter and by 5% YoY
MRK's P/S is 32% above its last 4 quarters average of 3.7 and 16% above its 5-year quarterly average of 4.2
The revenue has grown by 2.9% YoY

Efficiency

How efficient is Merck business performance
The company's return on assets has shrunk by 54% YoY and by 52% QoQ
Merck's ROE has plunged by 53% YoY and by 51% from the previous quarter
The ROIC fell by 49% YoY and by 44% QoQ
The ROS has contracted by 42% from the previous quarter and by 40% YoY

Dividends

What is MRK's dividend history
Dividend details
DPS
$3.36
Dividend yield
2.58%
Payout ratio
94.1%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Merck financials performed over time
The total assets is 56% more than the total liabilities
MRK's quick ratio is down by 29% since the previous quarter and by 18% year-on-year
Merck's total liabilities has increased by 24% YoY
MRK's debt is 7% greater than its equity
The debt to equity has grown by 49% YoY and by 14% from the previous quarter
MRK's debt is up by 41% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.